Skip to main content

These battered biotech stocks are now buying opportunities as Elizabeth Warren climbs in the polls

Sen. Elizabeth Warren’s health-care reform crusade is rattling biotech investors — but that’s not the industry’s only problem, writes Michael Brush.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.